Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sorafenib and Cyclophosphamide/Topotecan in Relapsed and Refractory Neuroblastoma
NCT02298348Phase 1Active, not recruiting
- Sponsor
- New Advances in Neuroblastoma Therapy
- Start
- Oct 2015
- Primary completion
- Dec 2026
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 1, open-label, single-arm trial of sorafenib in neuroblastoma, sponsored by New Advances in Neuroblastoma Therapy. Primary endpoints: Maximum Tolerated Dose at 2 years and Adverse Events at 2 years. Started Oct 2015; status: active, not recruiting.
02
Drugs
sorafenib
03
Conditions
neuroblastoma
Beyond the preview
Go deeper on NCT02298348.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02298348.